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Background: Diagnosing a specific type of Interstitial Lung Disease (ILD) is a challenging process and often
necessitates that a Video-assisted Thoracoscopic Surgery (VATS) Lung Biopsy be performed. By analysing the proportion
of patients who have their treatment changed after undergoing a VATS lung biopsy, this study aimed to determine the
utility of performing this procedure in patients with ILD.
Methods: The clinical data from sixty-six patients with suspected ILD, who underwent VATS lung biopsies at the New
Royal Infirmary of Edinburgh (NRIE) in the period of 16th May 2011 – 11th February 2013, were analysed retrospectively.
The main outcome measures considered in this study were: CT scan differential diagnoses, VATS lung biopsy histological
differential diagnoses, post-VATS lung biopsy consensus diagnoses, 30-day mortality, surgical complications (minor and
major), resultant changes in treatment and responses to these changes in treatment.
Results: Following VATS biopsy a definite pathological diagnosis was made in 74.2% of cases. A change in treatment
was initiated in 47.2% of patients, including in 80% of patients diagnosed with Hypersensitivity Pneumonitis and 60% of
patients diagnosed with sarcoidosis. A positive response to treatment was experienced in 58% of patients whom
underwent a change in treatment. Only 54% of patients who received a consensus diagnosis of UIP after VATS lung
biopsy, had been given a differential diagnosis of “probable UIP” at CT scan. 15% of patients who received a differential
diagnosis of “probable UIP” at CT scan, had their diagnosis changed to Hypersensitivity Pneumonitis after lung biopsy.
There was one mortality (1.5%) in this series of patients and no other major complications. Minor complications to
surgery were experienced in 28.8% of patients.
Conclusions: This study highlights the effectiveness of performing VATS lung biopsies in patients with suspected ILD.
The procedure leads to a change in treatment in almost half of all patients, including in the vast majority of cases of
Hypersensitivity Pneumonitis. It also prevents what would be the inappropriate over-treatment of UIP. It has been
shown to be a relatively safe procedure and thus, should be performed in all patients with suspected ILD, indeterminate
in type from prior CT imaging.
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Interstitial Lung Disease (ILD) denotes a collection of
heterogeneous lung diseases which all primarily affect the
interstitium of the lung. ILD most commonly presents
with dyspnoea or a dry cough. Systemic features, such as
weight loss or fatigue, are also common at presentation.
On clinical examination, the patient will often be tachyp-
noeic and bibasal end inspiratory fine crackles may be
heard on auscultation. Clubbing of the digits and cyanosis
may occasionally occur in advanced disease and patients
generally exhibit a restrictive pattern on Pulmonary Func-
tion Testing.
There are reported to be more than 200 different sub-
types of ILD, so achieving a correct specific diagnosis is
often challenging in a patient with ILD. This is of vital
importance though, because the subtypes of ILD have
different management protocols.
Computerised Tomography (CT) scanning is more spe-
cific than chest radiography in diagnosing subtypes of ILD
[1]. One study reported CT scanning to carry a diagnostic
accuracy of 61-80% [2]. Indeed, a CT scan which is highly
typical of a particular type of ILD, may provide a physician
with sufficient confidence to make the diagnosis without
further investigation. For example, the presence of centri-
lobular nodules is highly typical of chronic Hypersensitivity
Pneumonitis (HP). Conversely, the presence of basal, sub-
pleural, reticular opacities, which are associated with hon-
eycombing and traction bronchiectasis, would be highly
typical of Usual Interstitial Pneumonia (UIP) and would
probably preclude the need for further investigation. In-
deed CT scanning has a diagnostic accuracy of over 90% in
making the diagnosis of UIP, if radiological features are
highly suggestive of the disease [3-6]. However, the CT
scans of many cases of ILD, do not display features highly
typical of a particular subtype of ILD; this is indeed the
case in around 50% of cases of UIP [5,6].
When a diagnosis has been not achieved by CT im-
aging, patients can be investigated by bronchoscopy,
with Bronchoalveolar Lavages (BALs) and Transbron-
chial Lung Biopsies (TBLBs) being performed. However,
on balance, BAL is of limited utility in the diagnostic
process for ILD, other than sometimes allowing for the
exclusion of malignancy [7], or infection [8]. However on
occasion it can be useful in detecting rare forms of ILD
[9]. The diagnosing potential of TBLB is also unspectacu-
lar for many cases of ILD. A specific diagnosis is achieved
in the range 29 - 79% of reported cases referred for the
TBLB [10-14]. There are two main reasons for this: firstly,
the procedure only allows the clinician to obtain a very
small specimen of tissue and secondly, biopsies can only
be obtained from within the peribronchial sheath.
A specific diagnosis remains unavailable to one third of
all patients with ILD even after the procedures highlighted
above have been conducted [15-18]. So for this sizeablegroup of patients, the only option remaining is for a
Surgical Lung Biopsy (SLB). However, such an operation
is not without its risks to the patient; indeed SLB does
carry a slight risk of mortality. In recent years Video-
assisted Thoracoscopic Surgery (VATS) has replaced the
older, more invasive method, of performing a minithora-
cotomy in these patients.
The objective of this study was to assess the benefit of
performing VATS to obtain a histological diagnosis in
patients with ILD, indeterminate in type on CT imaging.
The benefit was measured with respect to the diagnostic
ability of this procedure in obtaining a Definite Patho-
logical Diagnosis (DPD), as well as assessing the propor-
tion of patients who have their treatment changed as a
result of VATS being performed. Close attention was
also paid to the safety of this procedure.
Method
Seventy nine patients with suspected ILD, who consecu-
tively underwent a VATS lung biopsy at the New Royal
Infirmary of Edinburgh in the period between 16th May
2011 - 11th February 2013 were retrospectively analysed.
Exclusion criteria included: patients whose likely diagnosis
was malignancy at CT scan (5 patients) and patients
whose CT scan results hadn’t been uploaded onto either
Trak-care system or the Picture Archiving and Communi-
cation System (PACS) used by NHS Lothian (8 patients).
All data was obtained by inspection of patients’ medical
records. The Lothian Regional Ethics Committee deemed
that the study was a service evaluation and therefore did
not require formal ethical review. The data collected in-
cluded: patient demographics (age, gender etc.); presenting
symptoms; differential diagnoses from CT scan; pulmon-
ary function test (PFT) readings; pre-operative treatment;
number, location and size of biopsy specimens; operative
complications and length of hospital stay.
Two of the minor postoperative complications experi-
enced in the patient cohort were “delayed wound healing”
and “prolonged neuropathic pain”. Delayed wound healing
was defined as the failure of surgical wounds to heal
within 30 days of the operation. Prolonged neuropathic
pain was defined as the failure of neuropathic pain to re-
solve within 30 days of the operation.
The decision to refer a patient for VATS lung biopsy
would be made at a Multi-Disciplinary Team (MDT)
meeting. VATS was carried out under general anaesthe-
sia and single lung ventilation. Patients were intubated
with a double lumen endobronchial tube and placed in
the lateral decubitus position. The standard 3-port VATS
technique was used. The thoracoscope was inserted into
the first port site; this was created in the seventh inter-
costal space, somewhere between the anterior axillary line
and the mid-axillary line. The locations of the two further
port sites could then be determined under video-guidance.
Table 1 Characteristics of patients
No. of patients: 66














Time between first presentation and VATS lung biopsy: 16.1 months









Pre-operative therapy (corticosteroid or other immunosuppressant): 16.7%
Table 2 Number, site and size of VATS lung biopsies
Number > 1: 42.2%
Biopsy volume: 16.8 cm2
Biopsy site:
Left lower lobe: 43.8%
Left upper lobe: 40.6%
Right lower lobe: 28.1%
Right middle lobe: 17.2%
Right upper lobe: 3.1%
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scopic linear cutter (Ethicon Endo-surgery, Cincinnati,
OH). Choice of biopsy site was guided by CT imaging.
The decision to take single or multiple biopsies was made
by the operating thoracic surgeon. A single 32 F chest
drain was inserted into one of the anterior port sites, with
the other two port sites being closed with sutures. Biopsies
were injected with formalin and immersed in a jar contain-
ing formalin, then sent to Pathology.
Further data was collected regarding: histological dif-
ferential diagnoses; consensus diagnoses formulated by
Respiratory Physicians; postoperative changes in treat-
ment; time taken for the initiation of treatment change
and response to change in treatment.
Response to treatment was determined by analysing
changes in symptoms, PFT performance, and imaging on
Chest X Ray or CT scan. In most cases, changes in these
clinical measures correlated, however, deterioration in any
one of these clinical measures prevented the case from be-
ing considered as a “positive response to treatment”.
There were limits to the data on Trak-care system:
PFT readings prior to VATS were only available for 55%
of patients; data regarding size of biopsies were only
available for 71% of patients; data concerning changes in
treatment were available for 80% of patients; and data
regarding response to treatment were available for 12
out of the 26 patients in which a change in treatment
was initiated.
Results
The characteristics of the 66 patient who underwent
VATS are summarised in Table 1. 53% of the cohort were
female and the average age of the cohort was 59 years. The
commonest symptoms on first presentation were dyspnoea
(73%) and a dry (36%) or productive (29%) cough. The
average length of time between when a patient first pre-
sented with symptoms to when the VATS procedure took
place was 16 months. The average FEV1 and FVC readings
in patients prior to VATS were 2.11 L and 2.71 L respect-
ively. Prior to VATS being performed, 25.8% of patients
had already undergone BAL and 7.6% had undergone a
TBLB, whilst steroid or immunosuppressive therapy had
already been initiated or trialled in 16.7% of patients.
Characteristics of the VATS lung biopsy procedure are
summarised in Table 2. More than one biopsy was taken
in 42.2% of patients. The average biopsy size was 16.8 cm2.
The most common sites for biopsy were: the left lower
lobe (44%), the left upper lobe (41%) and the right lower
lobe (28%).
Complications related to the VATS lung biopsy pro-
cedure are summarised in Table 3. There was one death
(30 day mortality rate: 1.5%) in the patient cohort. The
circumstances of this death were that the patient suffered
a sudden deterioration in respiratory function 10 daysafter surgery, thought to be secondary to sepsis, and sub-
sequently died on postoperative day 16; autopsy revealed
diffuse alveolar damage and severe interstitial pulmonary
fibrosis of unclassifiable type. There were no other major
complications seen in the patient cohort. Minor complica-
tions were experienced in 28.8% of patients; these included
small pneumothorax (10.6%), lower respiratory tract infec-
tion (6%) and surgical emphysema and prolonged neuro-
pathic pain (both 4.5%). The average duration of time that
a chest drain was left in situ was 1.15 days and the average
hospital stay was 3.5 days.
Table 3 Mortality and morbidity of VATS lung biopsies
30-day mortality: 1.5%





Prolonged neuropathic pain: 4.5%
Delayed wound healing: 3%
Persistent air leak: 1.5%
Conversion to open lung biopsy: 0%
Chest drain duration: 1.15 days
Hospital stay: 3.53 days
Table 5 Diagnostic accuracy of VATS lung biopsy and
postoperative rates of therapy change
Definite Pathological Diagnosis (DPD):
74.2%
Change in treatment (overall): 47.2%
Change in treatment in “DPD” cohort:
46.2%
Change in treatment in “no DPD”
cohort: 50%




Positive response to treatment: 58.3%
Time taken for change of treatment:
12.7 weeks
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CT scanning were UIP (in 28.8% of patients), hypersensitiv-
ity pneumonitis (24.2%), NSIP (18.2%), infection, Crypto-
genic Organising Pneumonia, sarcoidosis and Connective
Tissue Disease (all 13.6%) (Table 4).
A Definite Pathological Diagnosis (DPD) was achieved
from VATS lung biopsy in 74.2% of cases (Table 5).
The most common pathological differential diagnoses
made were Hypersensitivity Pneumonitis (31.8%) and
UIP (28.8%), followed by Connective Tissue Disease (CTD)
(13.6%), NSIP (12.1%) and sarcoidosis (10.6%) (Table 6).
Consensus diagnoses were formulated based on findings
from the CT scans and lung biopsies, in addition to consid-
eration of the overall clinical picture of each patient. The
most common consensus diagnoses made were: Hypersen-
sitivity Pneumonitis (22.2%), UIP (20.6%), sarcoidosis (9.5%)
and NSIP and CTD (both 7.9%). In 9.5% of patients, the
interstitial lung disease process occurring was deemed to
be unclassifiable (Table 7).
A change in treatment was initiated in 47.2% of pa-
tients subsequent to VATS being performed. A change
in treatment was initiated in: 80% of patients diagnosedTable 4 Differential diagnoses given after CT imaging
Ddx after CT scan No. of patients %
UIP 19 28.8







No differential given 6 9.1
Drug 4 6.1
Other 22 33.3with Hypersensitivity Pneumonitis; 60% of patients with
sarcoidosis and 10% of patients with UIP (Table 5). A
change in treatment was initiated in 46.2% of the pa-
tients who received a DPD and 50% of the patients who
did not receive a DPD (Table 5). Therapy change was
initiated on average 12.7 weeks after the VATS biopsy
(Table 5). Among the patients who underwent a change
in treatment, 58.3% demonstrated a positive response to
treatment (Table 5).
The differential diagnosis of “probable UIP” was re-
ported in the CT scans of 13 patients. Only 54% of these
patients received an eventual diagnosis of UIP, with 15%
of them each having HP and NSIP (Table 8, Figure 1).
83% of patients considered to have probable HP at CT
scan were eventually given a consensus diagnosis of HP.
33% of patients considered to have probable NSIP at
CT scan were eventually given a consensus diagnosis of
NSIP (Table 8).Table 6 Differential diagnoses given based on VATS
biopsies
Ddx of VATS biopsy No. of patients %






Pulmonary Langerhans Histiocytosis 3 4.6
Infection 3 4.6
Stoneworkers pneumoconiosis 2 3.0
End stage fibrosis 2 3.0
Other 21 31.8
Table 7 Consensus diagnoses given after VATS biopsies
Consensus diagnoses after VATS biopsy No. of patients %








End stage fibrosis 2 3.2
Vasculitis 2 3.2
Other 14 22.2
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considered as having “probable UIP” at CT scan (Table 9).
40% of patients given a consensus diagnosis of NSIP, and
14% of patients given a consensus diagnosis of HP were
considered as having “probable UIP” at CT scan (Table 9).
Discussion
Obtaining a specific diagnosis is a challenging process
for many patients with ILD. CT scanning achieves a cor-
rect diagnosis in only 61 - 80% of cases of ILD [2], whilst
the minimally invasive procedures, BAL and TBLB, have
limited value in this diagnostic setting. Hence almost
one third of patients with ILD will eventually require a
Surgical Lung Biopsy (SLB) to obtain a definite diagnosis,
with the procedure of choice in today’s surgical setting be-
ing Video-Assisted Thoracoscopic Surgery (VATS) [15-18].
Prior to VATS being performed, only 7.6% of patients
in this study had undergone a Transbronchial Lung Bi-
opsy (TBLB); this figure is comparable to that (11.9%)
reported in a similar study by Qureshi et al. [19]. These
figures reflect that for many cases of ILD, indeterminate
in type after CT imaging, obtaining a TBLB is deemed to









UIP Probable 13 7 2
UIP Possible 6 3 1
HP Probable 6 0 5
HP Possible 9 5 2
NSIP Probable 3 0 0
NSIP Possible 9 4 2
Sarcoidosis Probable 3 0 0
Sarcoidosis Possible 6 0 0
Proportional breakdown of postoperative consensus diagnoses given to probable/p
(HP), NSIP and sarcoidosis.Definite Pathological Diagnosis (DPD); such cases are in-
stead directly referred for a Surgical Lung Biopsy (SLB).
TBLBs are only likely to yield specific diagnoses in cases
whereby small specimens are expected to be diagnostic,
and particularly in forms of ILD with bronchocentric in-
volvement [20]. For instance, a much larger size of speci-
men than that obtained by a TBLB, is normally required
to make the diagnosis of UIP [21,22].
Amongst our group of 66 patients, there was only one
death as a result of the VATS procedure (30 day mortal-
ity rate: 1.5%). In fact, this was the only major complica-
tion encountered in the patient cohort. Other studies
have reported similar low mortality rates for VATS (0% -
3.17%), when performed to obtain a diagnosis of ILD
[19,23-26]. There have been studies which have reported
higher mortality rates for a Surgical Lung Biopsy (SLB)
being performed in this setting (4.8 - 24%), but all such
studies have had relatively higher proportions of their
patients undergoing Open Lung Biopsies (OLBs), a more
invasive surgical procedure than VATS [27-30]. Minor
post-operative complications were experienced in nine-
teen of our patients (28.8%), a figure which is higher than
that reported in other studies. Kreider et al. reported an
overall post-operative complication rate of 19.1% [25],
whilst the minor post-operative complication rate was
only 6.8% in the study by Blackhall et al. [27]. The vast
majority of the nineteen patients who experienced minor
post-operative complications in this study, did not have
their stay in hospital prolonged as a result, and indeed the
average hospital stay reported in our study was only
3.53 days. Therefore, on balance, the complete absence of
any major post-operative complications (including mortal-
ity) in sixty five out of the sixty-six patients included in
the study, gives us considerable reassurance about the
relative safety of the VATS procedure in this setting.
Patients included in this study had been highly se-
lected for: they all had forms of ILD which couldn’t be
diagnosed on CT scan. In consideration of this fact, we
would deem the diagnostic capabilities demonstrated bynd post-VATS biopsy consensus diagnoses
sensus diagnosis (after VATS biopsy) Correct
diagnosisNSIP Sarcoidosis Other
2 1 1 54%
1 0 1 50%
0 0 1 83%
0 2 0 22%
1 0 2 33%
2 0 1 22%
0 2 1 67%
0 3 3 50%











Figure 1 Proportional breakdown of postoperative consensus
diagnoses given to CT differential diagnoses of “probable UIP”.
Morris and Zamvar Journal of Cardiothoracic Surgery 2014, 9:45 Page 6 of 8
http://www.cardiothoracicsurgery.org/content/9/1/45VATS in our study – in obtaining a DPD in around three
quarters of cases – to be substantial. There is marked
variation between what previous studies have reported
the rate of DPDs being yielded by SLBs to be; figures
vary between 34 - 100% [24,26,27,31-33]. A figure com-
parable to this study (69.9%) was recently reported by
Blackhall et al. [27], whilst two other studies reported a
DPD being obtained from 100% of the patients with sus-
pected ILD, undergoing the VATS procedure [24,26]. It
is worth noting, our data did not show there to be a re-
duced rate of therapy change among the 25.8% of pa-
tients with no DPD after VATS. This may indicate that
even when VATS fails to provide a DPD, it can still be of
great help to the clinician, in excluding various differen-
tial diagnoses proposed by prior CT imaging, and thus
narrowing the diagnostic possibilities for a patient.
That VATS biopsy provoked a change in treatment in
almost half of our patients gives strong suggestion that
this procedure is of considerable benefit to patients with
ILD. Other studies have reported similar numbers of pa-
tients having their therapy altered after SLB. In a recent
study by Blackhall et al., 45.6% of patients had their ther-
apy altered [27], whilst Kramer et al. reported a change in
therapy in 46% of its patients after SLB [34]. Fifty four per
cent of patients with ILD had their therapy altered after




cases UIP HP NSI
UIP 13 7 (54%) 0 0
HP 14 2 (14%) 5 (36%) 0
Sarcoidosis 6 1 (17%) 0 0
NSIP 5 2 (40%) 0 1 (20
Malignancy 1 0 0 0
Proportional breakdown of preoperative “probable diagnoses at CT scan” given to c
and malignancy.percentage of patients received a change in therapy
(84.2%) in their report of 196 patients by Lee et al. [30].
Our data also demonstrates there to be a clinical benefit
for the majority of patients who have undergone a change
in therapy after VATS: 58% of our patients demonstrated
a positive response to treatment. A similar proportion of
patients (63.3%) were shown to display a clinical improve-
ment after SLB in the study by Lee et al. too [30].
However, it was not just by provoking an initiation of
new treatment that long term management of these pa-
tients was aided by obtaining a VATS lung biopsy. We
would also argue that VATS biopsy was of benefit to pa-
tients receiving a UIP diagnosis. UIP was the second
commonest consensus diagnosis made amongst our pa-
tients. The progression of UIP has been shown to be un-
affected by pharmacological intervention, and thus NICE
currently does not recommend pharmacological interven-
tion for most cases of UIP; the guidelines state: “there is
no conclusive evidence to support the use of any drugs to
increase survival of people with IPF” [35]. A change in
treatment was initiated in only 9% of our patients diag-
nosed with UIP. Thus steroid therapy was withheld in the
overwhelming majority of our patients who received a
diagnosis of UIP. Crucially, only 54% of patients receiving
a diagnosis of UIP after undergoing a VATS lung biopsy
had originally been given a diagnosis of “probable UIP” at
CT scan (Table 9). The VATS lung biopsy particularly
served to benefit the remaining 46% of patients whose CT
scans had not indicated “probable UIP”: if these patients
had not undergone VATS lung biopsies, they may have
ended up with alternative ILD diagnoses and as a result,
been unnecessarily exposed to the toxic side effects of im-
munosuppressive therapy.
Whilst UIP was the most frequent differential diagnosis
made at CT scan among our patients, it was only the sec-
ond most common differential reported at VATS biopsy,
and likewise the second most common disease assigned
as a consensus diagnosis. Hypersensitivity Pneumonitis
instead, became the foremost ILD type diagnosed in our
patient cohort after VATS (Table 7). Hypersensitivity
Pneumonitis, in contrast to UIP, is a form of ILD which
does respond to steroid therapy [20]. Indeed steroid therapynd post-VATS biopsy consensus diagnoses
Probable diagnosis at CT scan
P Sarcoidosis Malignancy Other Ambiguous
0 0 2 4
0 0 2 5
2 (33%) 0 0 3
%) 0 1 (20%) 1 0
0 0 1 0
onsensus diagnoses of UIP, Hypersensitivity Pneumonitis (HP), sarcoidosis, NSIP
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this figure would have been even higher if it wasn’t for the
fact that steroid therapy was contraindicated in one particu-
lar patient with osteoporosis.
Our data shows VATS biopsy to be useful in that it
frequently manages to differentiate HP from UIP: 15% of
CT cases which were considered as “probable UIP” on CT
scan, were proven to be HP on histology (Table 8, Figure 1).
Moreover, 14% of the cases of biopsy-proven HP had earl-
ier been considered as “probable UIP” on CTscan (Table 9).
There are certain radiological features which are particu-
larly specific to HP (centrilobular nodules) or UIP (basal,
subpleural, reticular opacities associated with traction
bronchiectasis) and allow for their confident differentiation
on CT scan. However, when these disease-specific radio-
logical features are absent, and when radiological patterns
common to both HP and UIP (honeycombing, ground
glass attenuation) predominate on CT scan, it is difficult to
distinguish between these two diseases with a high level of
confidence. Lynch et al. found that the accuracy of distin-
guishing UIP from HP on CT scan falls from 90%, when
the CT diagnosis is made with a high level of confidence,
to 60%, when the features on CT scan don’t allow a high
level of confidence [36]. Silva et al. reported that UIP can
be confidently distinguished from HP (or NSIP) by CT
imaging in only 53% of cases [37]. In a more recent
study by Sverzellati et al., thoracic radiologists retrospect-
ively reviewed the CT scans of 55 patients with biopsy-
proven UIP; a probable diagnosis of HP was made in 7%
of these CT scans [38].
Non-Specific Interstitial Pneumonia (NSIP) is another
variant of ILD which can often be difficult to distinguish
from UIP on CT scan alone, and this was also shown in
our data: 40% of the cases of biopsy-proven NSIP, had
been considered as “probable UIP” on CT scan (Table 9).
One study demonstrated an incorrect diagnosis of prob-
able NSIP to be retrospectively made in 34% of patients
with biopsy-proven UIP [3]. In a retrospective study of
55 patients with biopsy-proven UIP, by Sverzellati et al.,
33% of CT scans retrospectively analysed, were classed
as probable NSIP [38]. Again, the clinical implications of
being able to accurately distinguish NSIP from UIP are
considerable: NSIP, as well as having a substantially bet-
ter prognosis than UIP, is also a disease which is much
more likely to be responsive to immunosuppressive ther-
apy. Indeed steroid therapy was initiated in 40% of the
patients who were given a consensus diagnosis of NSIP
in our study.
Conclusion
It is beneficial to obtain a VATS lung biopsy in patients
with ILD indeterminate in type from prior investigation.
With the deployment of this procedure, a specific diag-
nosis can be obtained in roughly three quarters of thesepatients, with a resultant change in treatment being
prompted in almost half of these patients, including in
the vast majority of Hypersensitivity Pneumonitis cases.
It also ensures that patients with UIP aren’t given inappro-
priate immunosuppressive treatment. It is recommended
that the VATS procedure is performed for all patients with
ILD indeterminate in type from prior investigation.
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